vs
Ginkgo Bioworks Holdings, Inc.（DNA）与PCB BANCORP（PCB）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是PCB BANCORP的1.1倍（$33.4M vs $29.2M），PCB BANCORP同比增速更快（11.3% vs -23.8%），PCB BANCORP自由现金流更多（$24.4M vs $-47.7M），过去两年PCB BANCORP的营收复合增速更高（10.4% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
PCB BANCORP旗下的PCB银行是一家总部位于加利福尼亚州的美国社区银行，主要服务韩裔美国社群，提供商业银行服务，目前在全美8个州设有分支机构，规模在韩资背景美国银行中位列第三，仅次于希望银行与韩美银行。
DNA vs PCB — 直观对比
营收规模更大
DNA
是对方的1.1倍
$29.2M
营收增速更快
PCB
高出35.1%
-23.8%
自由现金流更多
PCB
多$72.1M
$-47.7M
两年增速更快
PCB
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $29.2M |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 45.0% |
| 净利率 | — | — |
| 营收同比 | -23.8% | 11.3% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-1.41 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAPCB
| Q4 25 | $33.4M | $29.2M | ||
| Q3 25 | $38.8M | $30.4M | ||
| Q2 25 | $49.6M | $29.3M | ||
| Q1 25 | $48.3M | $26.9M | ||
| Q4 24 | $43.8M | $26.2M | ||
| Q3 24 | $89.0M | $25.3M | ||
| Q2 24 | $56.2M | $24.2M | ||
| Q1 24 | $37.9M | $23.9M |
净利润DNAPCB
| Q4 25 | — | — | ||
| Q3 25 | $-80.8M | $11.4M | ||
| Q2 25 | $-60.3M | $9.1M | ||
| Q1 25 | $-91.0M | $7.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-56.4M | $7.8M | ||
| Q2 24 | $-217.2M | $6.3M | ||
| Q1 24 | $-165.9M | $4.7M |
营业利润率DNAPCB
| Q4 25 | -211.9% | 45.0% | ||
| Q3 25 | -231.8% | 52.3% | ||
| Q2 25 | -132.1% | 43.3% | ||
| Q1 25 | -184.1% | 40.2% | ||
| Q4 24 | -236.3% | 39.3% | ||
| Q3 24 | -62.0% | 42.2% | ||
| Q2 24 | -396.7% | 36.3% | ||
| Q1 24 | -469.1% | 27.2% |
净利率DNAPCB
| Q4 25 | — | — | ||
| Q3 25 | -207.9% | 37.5% | ||
| Q2 25 | -121.6% | 31.0% | ||
| Q1 25 | -188.2% | 28.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -63.3% | 30.8% | ||
| Q2 24 | -386.4% | 25.9% | ||
| Q1 24 | -437.3% | 19.6% |
每股收益（稀释后）DNAPCB
| Q4 25 | $-1.41 | $0.65 | ||
| Q3 25 | $-1.45 | $0.78 | ||
| Q2 25 | $-1.10 | $0.62 | ||
| Q1 25 | $-1.68 | $0.53 | ||
| Q4 24 | $-1.91 | $0.46 | ||
| Q3 24 | $-1.08 | $0.52 | ||
| Q2 24 | $-4.23 | $0.43 | ||
| Q1 24 | $-3.32 | $0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $207.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $390.0M |
| 总资产 | $1.1B | $3.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNAPCB
| Q4 25 | $422.6M | $207.1M | ||
| Q3 25 | $495.5M | $369.5M | ||
| Q2 25 | $559.4M | $263.6M | ||
| Q1 25 | $325.3M | $214.3M | ||
| Q4 24 | $561.6M | $198.8M | ||
| Q3 24 | $616.2M | $193.1M | ||
| Q2 24 | $730.4M | $177.6M | ||
| Q1 24 | $840.4M | $239.8M |
股东权益DNAPCB
| Q4 25 | $508.6M | $390.0M | ||
| Q3 25 | $559.8M | $384.5M | ||
| Q2 25 | $613.0M | $376.5M | ||
| Q1 25 | $647.4M | $370.9M | ||
| Q4 24 | $716.1M | $363.8M | ||
| Q3 24 | $797.9M | $362.3M | ||
| Q2 24 | $833.1M | $353.5M | ||
| Q1 24 | $987.3M | $350.0M |
总资产DNAPCB
| Q4 25 | $1.1B | $3.3B | ||
| Q3 25 | $1.2B | $3.4B | ||
| Q2 25 | $1.2B | $3.3B | ||
| Q1 25 | $1.3B | $3.2B | ||
| Q4 24 | $1.4B | $3.1B | ||
| Q3 24 | $1.5B | $2.9B | ||
| Q2 24 | $1.6B | $2.9B | ||
| Q1 24 | $1.6B | $2.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $26.6M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $24.4M |
| 自由现金流率自由现金流/营收 | -142.8% | 83.6% |
| 资本支出强度资本支出/营收 | 0.0% | 7.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $46.0M |
8季度趋势，按日历期对齐
经营现金流DNAPCB
| Q4 25 | $-47.7M | $26.6M | ||
| Q3 25 | $-31.6M | $16.4M | ||
| Q2 25 | $-40.3M | $4.9M | ||
| Q1 25 | $-51.5M | $2.3M | ||
| Q4 24 | $-42.4M | $39.0M | ||
| Q3 24 | $-103.5M | $11.9M | ||
| Q2 24 | $-84.4M | $14.6M | ||
| Q1 24 | $-89.3M | $8.2M |
自由现金流DNAPCB
| Q4 25 | $-47.7M | $24.4M | ||
| Q3 25 | — | $16.2M | ||
| Q2 25 | $-40.3M | $3.8M | ||
| Q1 25 | $-59.1M | $1.6M | ||
| Q4 24 | $-56.1M | $34.9M | ||
| Q3 24 | $-118.6M | $11.9M | ||
| Q2 24 | $-111.4M | $12.8M | ||
| Q1 24 | $-96.0M | $6.0M |
自由现金流率DNAPCB
| Q4 25 | -142.8% | 83.6% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | -81.2% | 13.1% | ||
| Q1 25 | -122.4% | 6.0% | ||
| Q4 24 | -128.0% | 133.2% | ||
| Q3 24 | -133.2% | 46.8% | ||
| Q2 24 | -198.2% | 53.1% | ||
| Q1 24 | -252.9% | 25.2% |
资本支出强度DNAPCB
| Q4 25 | 0.0% | 7.5% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.1% | 3.7% | ||
| Q1 25 | 15.8% | 2.8% | ||
| Q4 24 | 31.3% | 15.5% | ||
| Q3 24 | 16.9% | 0.1% | ||
| Q2 24 | 48.1% | 7.3% | ||
| Q1 24 | 17.7% | 9.3% |
现金转化率DNAPCB
| Q4 25 | — | — | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.52× | ||
| Q2 24 | — | 2.33× | ||
| Q1 24 | — | 1.76× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
PCB
暂无分部数据
